NAT2 and breast cancer: As shown in Fig. 3, rapid acetylator congenic rats had a significantly (p<0.05) shorter latency for development of their first palpable mammary tumor compared to slow acetylator NAT2 congenic rats after administration of MNU in females treated at either 3 or 8 weeks of age.